Search:
This item requires a subscription.
Oral anticoagulation for atrial fibrillation Thrombus, Volume 12, Number 4.
The benefit in symptomatic atrial fibrillation (AF) of oral anticoagulant therapy is well established in clinical trials. Overall, stroke is five to six times more prevalent in patients with AF, with a 1% risk per year for patients over 65 years with no risk factors, rising to 12% per year for patients over 65 years with previous stroke, transient ischaemic attack (TIA) or venous thromboembolic disease. Furthermore, stroke in AF patients is associated with a greater mortality, morbidity, disability and longer inpatient admissions.
To view this item, select one of the options below:
Purchase access
Sign in
email address
Password
Important
All the articles are in PDF format.
To view the articles you will need Adobe Acrobat Reader.
To download a copy, free of charge, please click here.